Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yoshinari Muto
Institution:
Fujita Health University
Observed institution:
Fujita Health University
ORCID:
0009-0009-7578-1132
Observed ORCID:
0009-0009-7578-1132
OpenAlex ID:
A5066299303
Tryptophan 2,3‐dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma
2021
·
Makoto Sumitomo
, Kiyoshi Takahara
, et al.
·
Cancer Science
·
34
PDF
Genotype-phenotype correlation of renal lesions in the tuberous sclerosis complex
2022
·
Yoshinari Muto
, Hitomi Sasaki
, et al.
·
Human Genome Variation
·
11
PDF
Impact of an enhanced recovery protocol in frail patients after intracorporeal urinary diversion
2024
·
Kenji Zennami
, Mamoru Kusaka
, et al.
·
British Journal of Urology
·
10
PDF
Exposure to ileal feces with frailty-associated dysbiosis elevates gastrointestinal complication risk after intracorporeal urinary diversion
2025
·
Kenji Zennami
, Takuhisa Nukaya
, et al.
·
Scientific Reports
·
3
PDF
Deep‐learning segmentation to guide bladder neck recognition in robot‐assisted radical prostatectomy
2026
·
Yoshinari Muto
, Kenji Zennami
, et al.
·
British Journal of Urology
·
1
Microbiota of the distal ileum under antibiotic prophylaxis: Does fecal exposure during intracorporeal intestinal urinary diversion increase gastrointestinal complications?
2024
·
Kenji Zennami
, Takuhisa Nukaya
, et al.
·
Research Square
Abstract 3972: Novel renal cell carcinoma therapy targeting glutaminolysis
2023
·
Yoshinari Muto
, Akihito Takeuchi
, et al.
·
Cancer Research
Abstract 4331: Comprehensive analysis of copy number variation and sensitivity to targeted therapy in renal cell carcinoma using in-house cancer gene panel testing
2023
·
Akhito Takeuchi
, Mayu Takeda
, et al.
·
Cancer Research
Mp04-08 Comprehensive Analysis of Copy Number Variation and Sensitivity to Targeted Therapy in Renal Cell Carcinoma Using In-house Cancer Gene Panel Testing
2023
·
Akihito Takeuchi
, Mayu Takeda
, et al.
·
The Journal of Urology
PDF
Mp04-11 Targeting Glutamine Addiction With Potent Drug Combination Therapy for Renal Cell Carcinoma
2023
·
Yoshinari Muto
, Akihito Takeuchi
, et al.
·
The Journal of Urology
PDF
Pd01-03 Alanine–serine–cysteine Transporter 2 in Glutamine Metabolism Is a Therapeutic Target for Renal Cell Carcinoma
2022
·
Yoshinari Muto
, Makoto Sumitomo
, et al.
·
The Journal of Urology
Mp39-01 System Asc Transporter 2, a Key Enzyme for Glutamine Pathway, Is a Possible Biomarker for Metastatic Progression and Survival in Renal Cell Carcinoma
2021
·
Yoshinari Muto
, Makoto Sumitomo
, et al.
·
The Journal of Urology
Show more works
View as search
Works count:
12
Citation count:
59
H-index:
3
I10-index:
3
Year
Topic
Type